Long term safety of etanercept in elderly subjects with rheumatic diseases

R. Fleischmann, S. W. Baumgartner, M. H. Weisman, T. Liu, B. White, P. Peloso

Research output: Contribution to journalArticle

Abstract

Objectives: To determine the long term safety profile of the tumour necrosis factor (TNF) antagonist etanercept in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) aged ≥65 years in comparison with subjects aged

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume65
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Psoriatic Arthritis
Ankylosing Spondylitis
Rheumatic Diseases
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Safety
Etanercept

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Fleischmann, R., Baumgartner, S. W., Weisman, M. H., Liu, T., White, B., & Peloso, P. (2006). Long term safety of etanercept in elderly subjects with rheumatic diseases. Annals of the Rheumatic Diseases, 65(3), 379-384. https://doi.org/10.1136/ard.2005.035287

Long term safety of etanercept in elderly subjects with rheumatic diseases. / Fleischmann, R.; Baumgartner, S. W.; Weisman, M. H.; Liu, T.; White, B.; Peloso, P.

In: Annals of the Rheumatic Diseases, Vol. 65, No. 3, 03.2006, p. 379-384.

Research output: Contribution to journalArticle

Fleischmann, R, Baumgartner, SW, Weisman, MH, Liu, T, White, B & Peloso, P 2006, 'Long term safety of etanercept in elderly subjects with rheumatic diseases', Annals of the Rheumatic Diseases, vol. 65, no. 3, pp. 379-384. https://doi.org/10.1136/ard.2005.035287
Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Annals of the Rheumatic Diseases. 2006 Mar;65(3):379-384. https://doi.org/10.1136/ard.2005.035287
Fleischmann, R. ; Baumgartner, S. W. ; Weisman, M. H. ; Liu, T. ; White, B. ; Peloso, P. / Long term safety of etanercept in elderly subjects with rheumatic diseases. In: Annals of the Rheumatic Diseases. 2006 ; Vol. 65, No. 3. pp. 379-384.
@article{a7b5479ce6714887b7cb4134d0892ba2,
title = "Long term safety of etanercept in elderly subjects with rheumatic diseases",
abstract = "Objectives: To determine the long term safety profile of the tumour necrosis factor (TNF) antagonist etanercept in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) aged ≥65 years in comparison with subjects aged",
author = "R. Fleischmann and Baumgartner, {S. W.} and Weisman, {M. H.} and T. Liu and B. White and P. Peloso",
year = "2006",
month = "3",
doi = "10.1136/ard.2005.035287",
language = "English (US)",
volume = "65",
pages = "379--384",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Long term safety of etanercept in elderly subjects with rheumatic diseases

AU - Fleischmann, R.

AU - Baumgartner, S. W.

AU - Weisman, M. H.

AU - Liu, T.

AU - White, B.

AU - Peloso, P.

PY - 2006/3

Y1 - 2006/3

N2 - Objectives: To determine the long term safety profile of the tumour necrosis factor (TNF) antagonist etanercept in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) aged ≥65 years in comparison with subjects aged

AB - Objectives: To determine the long term safety profile of the tumour necrosis factor (TNF) antagonist etanercept in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) aged ≥65 years in comparison with subjects aged

UR - http://www.scopus.com/inward/record.url?scp=33144490233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144490233&partnerID=8YFLogxK

U2 - 10.1136/ard.2005.035287

DO - 10.1136/ard.2005.035287

M3 - Article

VL - 65

SP - 379

EP - 384

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 3

ER -